Biotechnology -

Filter

Current filters:

Popular Filters

151 to 175 of 2106 results

Nanobiotix outlines development plan for NBTXR3 in soft tissue sarcoma

11-02-2014

Nanobiotix, a French nanomedicine company focused on cancer therapy, has announced today its development…

BiotechnologyNanobiotixNBTXR3OncologyResearch

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

11-02-2014

US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Alchemia announces appointment of Santo Costa as chairman

Alchemia announces appointment of Santo Costa as chairman

11-02-2014

Australia-based biotech company Alchemia has announced the appointment of Santo Costa as non-executive…

AlchemiaAustraliaBiotechnologyBoardroom

Actelion 2013 sales and earnings beat expectations

Actelion 2013 sales and earnings beat expectations

11-02-2014

Switzerland-based Actelion, Europe’s largest biotech firm, has reported financial results for full-year…

ActelionBiotechnologyFinancial

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Survey: Pharma CEOs on the importance of technology, demographics and innovation

Survey: Pharma CEOs on the importance of technology, demographics and innovation

07-02-2014

A global survey of chief executives has revealed the priorities and concerns of pharmaceutical and life…

BiotechnologyBoardroomGlobalMarkets & MarketingPharmaceutical

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Whistleblower law suit against Celgene unsealed

Whistleblower law suit against Celgene unsealed

07-02-2014

A US federal court yesterday unsealed a whistleblower/false claims law suit brought against US biotech…

BiotechnologyCelgeneLegalMarkets & MarketingNorth AmericaOncologyRevlimidThalomidUSA

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

All eyes on Sovaldi as Gilead reports financials, which were well above forecasts

All eyes on Sovaldi as Gilead reports financials, which were well above forecasts

05-02-2014

US antivirals-focused biotech firm Gilead Sciences posted financial results for the fourth quarter and…

BiotechnologyFinancialGilead SciencesSovaldi

Amarantus’ eltoprazine positive in mid-stage adult ADHD study

Amarantus’ eltoprazine positive in mid-stage adult ADHD study

04-02-2014

US biotech firm Amarantus Bioscience has released positive clinical data for eltoprazine in a Phase IIa…

Amarantus BioscienceBiotechnologyeltoprazineNeurologicalResearch

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

04-02-2014

A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize…

BiotechnologyInterviewsPharmaceuticalResearchUK

Biogen’s MS drug Tecfidera approved in EU

Biogen’s MS drug Tecfidera approved in EU

03-02-2014

US biotech firm Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the European Commission…

Biogen IdecBiotechnologyEuropeNeurologicalRegulationTecfidera

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Celgene profits hit by higher R&D, acquisition costs

Celgene profits hit by higher R&D, acquisition costs

31-01-2014

US biotech major Celgene reported financial results for the fourth-quarter and full-year 2013, with final…

BiotechnologyCelgeneFinancial

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

Janssen’s psoriasis drug Stelara set to generate $1.4 billion by 2015

30-01-2014

Psoriasis drug Stelara (ustekinumab), from US health care giant Johnson & Johnson’s subsidiary Janssen…

BiotechnologyDermatologicalsJanssen BiotechMarkets & MarketingStelara InjectionUSA

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Fluidigm and DVS Sciences announce merger worth $207.5 million

30-01-2014

US-based microfluidic systems developer Fluidigm Corporation (NASDAQ:FLDM) has entered into a definitive…

BiotechnologyMergers & AcquisitionsUSA

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

30-01-2014

In a series of letters to be sent to state Medicaid directors starting this week, Michael Weinstein,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingSovaldiUSA

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

29-01-2014

US biotech firm Biogen Idec reported full year and fourth quarter 2013 results that beat consensus Wall…

Biogen IdecBiotechnologyFinancialTecfidera

151 to 175 of 2106 results

Back to top